Skip to main content

Carl Icahn says Illumina’s appeal of FTC order to divest Grail is ‘an almost impossible battle’

Carl Icahn shares common ground with the FTC, which argued that Illumina's acquisition of cancer test developer Grail would stifle competition and innovation.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.